Anders Dyhr Toft waves goodbye to Novo Nordisk after 18 years to become the CMO of Synact: "It's going to be more DIY-based"

After almost two decades working for Novo Nordisk, Anders Dyhr Toft changes the scenery of his professional life to biotech company Synact Pharma to be the new CMO. According to the person in question, he felt the need to try out a different culture and pacing, as well as a new level of risk-taking.

Synact Pharma's new Chief Medical Officer Anders Dyhr Toft | Photo: Per Fledelius / PR

A freer bird now, but with smaller wings.

This is how Anders Dyhr Toft describes his life after swapping the job of corporate vice president for commercial innovation at Novo Nordisk for that of Chief Medical Officer at biotech firm Synact Pharma.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs